During 6–12 months of implanted ECB-NGF devices and hmNGF-delivery into the basal forebrain of AD patients, we observed increased glucose metabolism, decreased rates of brain atrophy, more stable cognitive function, and improvement of the level of cholinergic markers in the cerebrospinal fluid (CSF) [16,18,19]. This evidence concerns the gene NGF and Alzheimer disease.